Position in SCYX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,577,206
New position
Shares Held
387,520
first reported quarter
Ownership
3.89%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 39 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Woodline Partners LP holds $232,519,537 across 16 Drug Manufacturers - Specialty & Generic names. SCYX ranks #14 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,189,584 | $40,303,105 | |
| 2 | ELAN |
Elanco Animal Health Inc
|
1,612,986 | $39,695,585 | |
| 3 | SUPN |
Supernus Pharmaceuticals, Inc.
|
708,276 | $32,941,916 | |
| 4 | ALKS |
Alkermes plc.
|
560,282 | $29,358,776 | |
| 5 | PBH |
Prestige Consumer Healthcare Inc.
|
359,721 | $17,004,011 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
846,387 | $15,201,110 | |
| 7 | VTRS |
Viatris Inc
|
803,143 | $12,753,910 | |
| 8 | UTHR |
UNITED THERAPEUTICS Corp
|
23,074 | $12,502,185 |
All Filings in SCYX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,577,206 | 387,520 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||